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Abstract 
Peroxisome proliferator-activated receptor gamma (PPARγ), a ligand-activated 
transcriptional factor involved in the regulation of glucose and lipid metabolism, has gained 
interest as a potential therapeutic target in multiple sclerosis (MS) due to its potent 
immunoregulatory properties and the therapeutic efficacy of its ligands in experimental 
autoimmune encephalitis (EAE). Elevated expression of PPARγ has been observed in the 
spinal cord of EAE mice and in an in vitro model of antigen-induced demyelination; however, 
no reports have yet been available on the PPARγ status in the central nervous system of 
human individuals with MS. Aiming to identify a possible alteration, the present study 
assessed the levels of PPARγ protein in the cerebrospinal fluid (CSF) of MS patients via 
ELISA technique. We report a pronounced elevation in the CSF levels of PPARγ in MS 
patients (n = 35) compared to non-inflammatory controls (n = 22). This elevation was 
independent of blood-CSF barrier integrity, but correlated with CSF white blood cell count 
and IgG index, associating the observed elevation with neuroinflammation. Controlling for 
potential confounders, the CSF levels of PPARγ further displayed a moderate but significant 
association with clinical severity. Corroborating with prior experimental findings, these 
results may contribute to our understanding about the role of PPARγ in MS, and may 
implicate this protein as a potential CSF biomarker of the disease. 
Key words: peroxisome proliferator-activated receptor gamma; multiple sclerosis; 
cerebrospinal fluid; ELISA; biomarker. 
 
  
 1. Introduction 
 
Peroxisome proliferator-activated receptors (PPARs) are members of a nuclear 
hormone receptor superfamily of ligand-activated transcriptional factors that also includes 
thyroid, steroid and retinoid receptors. Out of the three subtypes known (PPARα, PPARβ/δ 
and PPARγ), PPARγ has been the most extensively investigated. PPARγ is known to be 
critically involved in the regulation of glucose and lipid metabolism, but more recent results 
also revealed an important role of PPARγ in the regulation immune response [6], gathering an 
increasing research interest in the field of disorders involving autoimmune processes in the 
pathomechanism, such as multiple sclerosis (MS) [11, 27]. 
MS is a chronic debilitating inflammatory central nervous system (CNS) disorder, 
characterized by demyelination, axonal and neuronal degeneration. The disease is supposed to 
be of autoimmune origin, in which encephalitogenic T-helper 1 (Th1) and interleukin 17 (IL-
17)-producing Th17 lymphocytes are proposed to be the main mediators [1]. In the past years, 
natural and synthetic agonists of PPARγ were shown to effectively ameliorate the course of 
experimental autoimmune encephalitis (EAE), a widely used experimental model of MS, by 
inhibiting the expansion of encephalitogenic T cells [8, 9, 13, 21, 23, 29, 35]. More recently, 
the activation of PPARγ in both human and murine CD4+ T cells have been shown to 
potently inhibit the differentiation towards the Th17 lineage [16], and the eicozapentaenoic 
acid-induced amelioration of EAE has been reported to be accompanied by increased PPARγ 
in association with decreased IL-17 expression in CNS-infiltrating CD4+ T cells [35]. 
Conversely, pharmacological inhibition of [28, 29] or a heterozygous deficiency in PPARγ 
[22, 28, 29] leads to an exacerbated course of EAE in mice in association with an augmented 
T cell response, suggesting altogether that the activation of the PPARγ pathway may be of 
therapeutic relevance in MS. Furthermore, elevated expression of PPARγ has been reported 
within the spinal cord of EAE mice [8, 9] and in an in vitro model of antigen-induced 
demyelination [12], supporting the notion that PPARγ may have a physiological role in the 
regulation of CNS inflammation in rodents. However, no reports have yet been available on 
the PPARγ status in the CNS of human individuals with MS. This study aimed to identify a 
possible alteration of PPARγ expression in MS, by assessing the levels of PPARγ protein in 
the CSF of MS patients. 
 
2. Patients, materials and methods 
The study included CSF samples of 35 MS patients meeting the 2009 McDonald 
criteria for definite relapsing-remitting (RR) MS. Non-inflammatory control samples were 
collected from 22 age- and sex-matched patients whose differential diagnostic process 
necessitated a lumbar puncture (LP) but the results of which along with that of the imaging 
modalities revealed no abnormalities in the CNS. Written informed consent was obtained 
from all subjects and the study was approved by the local Ethical Committee at the University 
of Szeged. The demographic, clinical and laboratory parameters of the cohorts are 
summarized in Table 1. LPs were performed between 2010 and 2013.	  The patients were free 
of immunomodulatory therapy, and for patients experiencing a relapse (n = 27) LP was 
performed before the initiation of corticosteroid therapy. 
Following the LP, CSF samples were centrifuged in 8.000 rpm for 10 minutes. The 
supernatants were stored in sterile polypropylene tubes in –80ºC until use. Commercially 
available sandwich enzyme-linked immunosorbent assay (ELISA) kits were applied for the 
quantitative detection of PPARγ, following the manufacturers’ instruction (Uscn Life Science 
Inc., Wuhan, China). Samples and standards were run in duplicates. The optical density 
values were detected at 450/560 nm with a plate reader (Awareness Technology Inc, Palm 
City, FL, USA) and the respective concentrations were read from the standard curves fitted by 
Sigmaplot 10.0 (Systat Software Inc., Richmond, CA, USA). The intraassay and interassay 
coefficients of variation were 9% and 15%, respectively. The analytical sensitivity of the 
assay is 51 pg/ml; values below the detection limit (12/22 in the Control vs 4/35 in the MS 
group) were interpolated from the standard curve to calculate median and provide measures 
for statistical computations. The CSF total protein concentration, the white blood cell count, 
the albumin quotient (CSF albumin / serum albumin) and the IgG index ((CSF IgG / serum 
IgG) / albumin quotient) were determined in our diagnostic laboratory and were available in 
the clinical records. The Expanded Disability Status Scale (EDSS) score was evaluated for 
each patient. To provide standardised clinical measures, EDSS scores were comprehensively 
revised by a trained MS investigator (K.B.) who was blind to the experimental findings. The 
statistical analysis was performed by SPSS Statistics 17.0 (SPSS Inc., Chicago, IL, USA). 
The normality of data was assessed by Shapiro-Wilk test. Due to the non-Gaussian 
distribution of the obtained data in the MS cohort, non-parametric tests (Mann-Whitney U, 
Spearman’s correlation) were used. Data in the text and in Table 1 are presented as median 
[interquartile range]. A p < 0.05 value was regarded as significant; p values of correlation 
analyses were corrected for multiple testing by the Bonferroni-Dunn method. Controlling for 
potential confounders, a binary logistic regression model and an ordinal regression model was 
established to assess the association of PPARγ with relapse and EDSS, respectively. 
 
3. Results 
In our study cohort, CSF levels of PPARγ were highly and significantly elevated in the 
CSF of patients with MS compared to Control (167.5 pg/ml [75.6–372.1 pg/ml] vs 40.4 pg/ml 
[16.5–73.1 pg/ml], p < 0.0005, Fig. 1). The elevation of PPARγ appeared to be independent of 
blood-CSF barrier integrity as suggested by the lack of correlations with CSF total protein 
levels (Spearman’s Rho = 0.110) and albumin quotient (Spearman’s Rho = –0.076) within the 
MS group. However, the CSF levels of PPARγ significantly and strongly correlated with the 
CSF cell count (p < 0.0005, Spearman’s Rho = 0.722, Fig. 2) and moderately correlated with 
the IgG index (p = 0.007, Spearman’s Rho = 0.528, Figure 2). Though the highest levels of 
PPARγ were measured in MS patients experiencing a relapse at sampling and the median 
level of PPARγ was considerably higher among patients in relapse compared to those in 
remission (197.39 pg/ml [87.58–397.50 pg/ml] vs 112.98 pg/ml [67.76–245.07 pg/ml]), CSF 
PPARγ level was not a significant predictor of relapse in a binary logistic regression model 
controlling for CSF cell count, total protein level, IgG index and albumin quotient as potential 
confounding covariates (p = 0.596, Exp(B) = 1.001, 95% confidence interval = 0.997–1.005, 
Wald Chi2 = 0.281, df = 1). Controlling for the same covariates in an ordinal regression 
model, CSF level of PPARγ displayed a moderate but significant (p = 0.011) positive 
association with EDSS with an estimate of 0.004 (95% confidence interval = 0.001–0.007; df 
 = 1), which calls for an odds ratio of 1.49 to have an increased EDSS by every 100 pg/ml 
elevation in the CSF concentration of PPARγ. 
	  
4. Discussion 
Our results demonstrate for the first time a pronounced elevation of PPARγ levels in 
the CSF of patients with MS, in association with increased CNS inflammatory parameters. 
These results are in line with the prior reports on elevated expression of PPARγ in the CNS of 
EAE mice [8, 9] and may reflect a possible physiological compensatory role of PPARγ in the 
regulation of CNS autoimmunity in humans. This experimentally demonstrated regulatory 
function is supposed to be primarily attributable to the attenuation of inflammatory cytokine 
expression within microglia/macrophages and astrocytes [30, 33, 37] and the (partly 
concomitant) suppression of the expansion of encephalitogenic Th1 [21], Th17 cells [16] and 
B lymphocytes [24], accompanied by a switch towards a Th2 response [10, 11]. In addition, 
activation of PPARγ expression in brain endothelial cells has been shown to be a negative 
regulator of lymphocytic transmigration [17]. Besides, PPARγ activation have also been 
demonstrated to have protective effects on neurons and oligodendrocytes [2, 10-12, 20, 26, 
34, 36]. Furthermore, the activation of PPARγ has been associated with the promotion of 
oligodendrocyte differentiation and myelin production [3, 7, 15, 25, 31, 34]. These properties 
may all contribute to the positive effects of PPARγ activation in experimental CNS 
inflammation, and may be exploited in MS therapy. Based on the experimental findings, two 
small clinical studies have been performed with the synthetic agonist pioglitazone, the results 
of both supporting that the use of PPARγ agonists may be beneficial in MS [14, 32]. 
Moreover, in a population-based study, the Pro12Ala polymorphism in the PPARG gene 
strongly associated with a delayed clinical onset of MS, which draws a further link between 
MS and PPARγ function [19]. 
The source of the elevated levels of PPARγ observed in this study, however, is not 
entirely clear, and its determination will require further investigations. It is known that PPARγ 
is expressed in neurons, oligodendrocytes, astrocytes, microglia/macrophages [3], T and B 
lymphocytes, dendritic cells [38] and brain endothelial cells [17]. In a murine EAE model of 
MS an increased expression of PPARγ has been reported in spinal cord homogenates [9] and 
in microglia/macrophages and astrocytes within the spinal cord lesions [8]. Furthermore, a 
strong upregulation of PPARγ has been observed in three-dimensional rat brain cultures 
following demyelination induced by antibodies directed against myelin oligodendrocyte 
glycoprotein [12]. Considering the neuropathological alterations in MS, the above listed 
experimental findings and our observation that PPARγ levels correlated with CSF 
inflammatory parameters, it is possible that PPARγ protein leaking out from 
injured/degenerating oligodendrocytes, neurons and astrocytes contribute to the observed 
elevation of its levels in the CSF. Considering that PPARγ upregulation has been 
demonstrated in activated macrophages [30] and activated T lymphocytes [4, 5], and that 
PPARγ levels correlated with the CSF cell count in our study, the contribution of such cellular 
origin to the observed phenomenon may not be fully excluded either; however, the fact that 
our CSF samples were centrifuged almost immediately after LP suggest that the extent of a 
putative cell disintegration within the obtained sample should most probably be insufficient to 
cause such a significant alteration in the concentration of PPARγ in the supernatant. Though 
future investigations are necessary to conclude on the exact source of the observed elevation, 
the possible sources discussed – in light with the findings of prior experimental studies – 
suggest that the level of PPARγ in the CSF may reflect the severity of CNS involvement, 
which could account for the observed positive association with EDSS in our study. 
The literature regarding alterations in PPARγ status in MS is rather sparse. Somewhat 
contradicting to our findings, another small clinical study examining peripheral white blood 
cells of MS patients reported decreased expression of PPARγ compared to control [18]. The 
findings of the two studies, however, are hard to compare, given that the studies focus on 
different compartments; furthermore, the patients enrolled in that study were either under 
immunomodulatory therapy or already in a secondary progressive phase, most probably 
representing different conditions compared to our untreated RR patients. 
 
5. Conclusions 
 CSF levels of PPARγ were pronouncedly elevated in MS patients. This elevation was 
independent of blood-CSF barrier integrity, strongly correlated with white blood cell count, 
moderately correlated with IgG index, and displayed a moderate association with clinical 
severity. These results may contribute to our understanding about the role of PPARγ in the 
pathogenesis MS, and implicate this protein as a potential CSF biomarker of the disease. 
Further research is necessary to determine the exact background of the observed alteration, 
and to assess the potential clinical relevance of this novel observation. 
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Fig. 1. PPARγ concentrations are elevated (p < 0.0005) in the CSF of patients with MS 
(n = 35) compared to control (n = 22). The box-plots present median and quartile values. 
Abbrevations: CSF, cerebrospinal fluid; MS, multiple sclerosis; PPARγ, peroxisome 
proliferator-activated receptor gamma. 
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Fig. 2. PPARγ levels correlate with white blood cell count and IgG index in the CSF of 
patients with MS. Abbrevations: CSF, cerebrospinal fluid; MS, multiple sclerosis; PPARγ, 
peroxisome proliferator-activated receptor gamma. 
 	  
	   	   	   Control MS p 
No. of subjects 	   	   22 35 - 
Female/male 	   	   13/9 21/14 0.946 
Age year 	   34.0 [26.2–47.3] 34.3 [27.5–42.1] 0.660 
Cell count M/l  1.0 [0.0–1.3] 4.0 [1.0–7.0] 0.001 
Total protein mg/l  325.0 [250.0–403.0] 400.0 [341.0–510.0] 0.007 
Albumin quotient x 103  - 6.0 [5.0–7.0] - 
IgG index   - 0.7 [0.6–0.9] - 
Relapse/remission 	   	   - 27/8 - 
EDSS 	   	   - 2.5 [2.0–3.0] - 
Disease duration month 	   - 18 [6.0–36.0] - 
Table 1. Demographic, laboratory and clinical parameters of the subject cohorts. The 
measured data are presented as median [interquartile range]. Abbrevations: EDSS, expanded 
disability status scale; MS, multiple sclerosis. 
 
